Department of Critical Care, Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.
Br J Anaesth. 2012 Dec;109(6):919-27. doi: 10.1093/bja/aes337. Epub 2012 Sep 30.
Fresh-frozen plasma (FFP) is widely used in critically ill patients, despite a weak evidence base. Factors that influence the decision to transfuse FFP before intravascular catheter insertion are poorly described.
We undertook a case-controlled study based on a prospective cohort study of 1923 admissions to 29 intensive care units in the UK. Non-bleeding patients with an international normalized ratio (INR) ≥1.5 who underwent intravascular catheterization, but no other invasive procedure, were identified. We compared patient characteristics, illness-related factors, and biochemical and haematological variables between patients who did or did not receive pre-procedural FFP.
One hundred and eighty-six patients fulfilled the criteria; 26 received FFP during the 24 h before line insertion (cases) and 160 did not (controls). Factors associated with greater use of prophylactic FFP by clinicians were pre-existing chronic liver disease (P=0.01), higher serum bilirubin before procedure (P=0.01), lower platelet count (P=0.01), higher activated partial thromboplastin time (P=0.001), lower fibrinogen (P=0.01), and concurrent red cell transfusion despite the absence of bleeding (P=0.001). There was no difference in pre-procedural INR [median (1st, 3rd quartile) cases: 1.95 (1.85, 2.6); controls 1.8 (1.6, 2.3); P=0.19]. The mean FFP dose was 11.1 ml kg(-1) (sd 5.7 ml kg(-1)); 53.8% of cases were transfused <10 ml kg(-1).
Chronic liver disease and more abnormal coagulation tests were associated with greater probability of pre-procedural FFP administration before vascular catheterization, whereas the severity of prothrombin time prolongation alone was not. FFP was more likely to be administered when red cells were also transfused, even in the absence of bleeding.
尽管证据基础薄弱,但新鲜冷冻血浆(FFP)在危重病患者中仍被广泛应用。在血管内导管插入术之前,影响输注 FFP 的决策的因素描述得很差。
我们进行了一项基于英国 29 个重症监护病房的前瞻性队列研究的病例对照研究。确定了在血管内导管插入术但未进行其他侵入性操作时,国际标准化比值(INR)≥1.5 的非出血患者。我们比较了接受和未接受术前 FFP 的患者的患者特征、与疾病相关的因素以及生化和血液学变量。
186 名患者符合标准;26 名患者在导管插入术前 24 小时内接受了 FFP(病例),160 名患者未接受(对照组)。临床医生更倾向于预防性使用 FFP 的因素包括:存在慢性肝病(P=0.01)、术前血清胆红素升高(P=0.01)、血小板计数降低(P=0.01)、活化部分凝血活酶时间延长(P=0.001)、纤维蛋白原降低(P=0.01)以及尽管没有出血但同时输注红细胞(P=0.001)。术前 INR 无差异[中位数(1 四分位数,3 四分位数)病例:1.95(1.85,2.6);对照组 1.8(1.6,2.3);P=0.19]。FFP 剂量平均为 11.1 ml/kg(标准差 5.7 ml/kg);53.8%的病例输注量<10 ml/kg。
慢性肝病和更多异常的凝血试验与血管导管插入术前更有可能进行术前 FFP 治疗相关,而单独凝血酶原时间延长的严重程度则不然。即使没有出血,当也输注红细胞时,更有可能输注 FFP。